Our Science

Creating a New Paradigm
with Shelf-Stable, Allogeneic Cellular Therapies

Cellphire Therapeutics is a clinical stage biotechnology company developing a portfolio of novel, stabilized, allogeneic, platelet-derived, cellular therapeutics. Benefiting from significant historical and planned funding from the US Government, our therapeutics utilize proprietary process and formulation technologies. Cellphire Therapeutics pipeline focuses on saving lives by bringing novel hemostatic products to patients most in need.

Cellphire has two investigational products in Phase 2 clinical trials, including FPH, a stabilized platelet-derived biologic, and Cryopreserved Platelets (CPP).

Lead Investigational Products

Thrombosomes Product
Thrombosomes®
Thrombosomes®, a platelet-derived freeze-dried hemostatic agent, is stable at ambient temperatures for up to 3 years, unlike standard platelets which can only be stored for 5 to 7 days.
Learn more
CPP Product
Cryopreserved Platelets (CPP)
CPP is comprised of frozen platelets stabilized with a cryoprotectant, DMSO (dimethyl sulfoxide). CPP can be cryopreserved for up to 5 years, unlike standard platelets which can only be stored for 5 to 7 days.
Learn more

Want to hear more about our trials and research?

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.